PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis

Autor: J M Ruiz de Almodóvar, F. Javier Oliver, Ana Cañuelo, José Antonio Muñoz-Gámez, Gilbert de Murcia, David Martín-Oliva, Rocío Aguilar-Quesada, M. Isabel Núñez, M. Teresa Valenzuela
Přispěvatelé: Cancérogenèse et mutagenèse moléculaire et structurale (CMMS), Centre National de la Recherche Scientifique (CNRS), Biotechnologie et signalisation cellulaire (BSC), Université de Strasbourg (UNISTRA)-Institut de recherche de l'Ecole de biotechnologie de Strasbourg (IREBS)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2005
Předmět:
MESH: Neoplasm Proteins
Poly (ADP-Ribose) Polymerase-1
MESH: Genes
p53

Apoptosis
MESH: Poly (ADP-Ribose) Polymerase-1
Quinolones
Biochemistry
Poly (ADP-Ribose) Polymerase Inhibitor
MESH: Drug Synergism
Membrane Potentials
MESH: Caspase 3
Tumor Cells
Cultured

Cytotoxic T cell
MESH: Tumor Suppressor Protein p53
Tumor Stem Cell Assay
bcl-2-Associated X Protein
biology
Caspase 3
MESH: Tumor Stem Cell Assay
Drug Synergism
MESH: 1-Naphthylamine
MESH: Drug Resistance
Neoplasm

Mitochondria
Neoplasm Proteins
Naphthalimides
MESH: Intracellular Membranes
[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Biomolecules [q-bio.BM]

1-Naphthylamine
MESH: Naphthalimides
Proto-Oncogene Proteins c-bcl-2
Caspases
Female
Poly(ADP-ribose) Polymerases
medicine.drug
Research Article
DNA damage
MESH: Mitochondria
Poly ADP ribose polymerase
Breast Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
MESH: Poly(ADP-ribose) Polymerase Inhibitors
MESH: Doxorubicin
Bcl-2-associated X protein
medicine
Humans
MESH: Membrane Potentials
Doxorubicin
MESH: bcl-2-Associated X Protein
[SDV.BBM]Life Sciences [q-bio]/Biochemistry
Molecular Biology

MESH: Tumor Cells
Cultured

Molecular Biology
MESH: Humans
MESH: Quinolones
MESH: Caspases
MESH: Apoptosis
MESH: Poly(ADP-ribose) Polymerases
Cell Biology
Intracellular Membranes
Genes
p53

Molecular biology
body regions
MESH: Proto-Oncogene Proteins c-bcl-2
Drug Resistance
Neoplasm

biology.protein
Cancer research
Tumor Suppressor Protein p53
MESH: Female
MESH: Breast Neoplasms
Zdroj: Biochemical Journal
Biochemical Journal, Portland Press, 2005, 386 (Pt 1), pp.119-25. ⟨10.1042/BJ20040776⟩
ISSN: 0264-6021
1470-8728
DOI: 10.1042/BJ20040776⟩
Popis: p53 deficiency confers resistance to doxo (doxorubicin), a clinically active and widely used antitumour anthracycline antibiotic. The purpose of the present study was to investigate the reversal mechanism of doxo resistance by the potent PARP [poly(ADP-ribose) polymerase] inhibitor ANI (4-amino-1,8-naphthalimide) in the p53-deficient breast cancer cell lines EVSA-T and MDA-MB-231. The effects of ANI, in comparison with doxo alone, on doxo-induced apoptosis, were investigated in matched pairs of EVSA-T or MDA-MB-231 with or without ANI co-treatment. Doxo elicited PARP activation as determined by Western blotting and immunofluorescence of poly(ADP-ribose), and ANI enhanced the cytotoxic activity of doxo 2.3 times and in a caspase-dependent manner. The long-term cytotoxic effect was studied by a colony-forming assay. Using this assay, ANI also significantly potentiates the long-term cytotoxic effect with respect to treatment with doxo alone. Decrease in mitochondrial potential together with an increase in cytochrome c release, association of Bax with the mitochondria and caspase 3 activation were also observed in the presence of ANI. Therefore PARP inhibition may represent a novel way of selectively targeting p53-deficient breast cancer cells. The underlying mechanism is probably a potentiation of unrepaired DNA damage, shifting from DNA repair to apoptosis due to the effective inhibition of PARP activity.
Databáze: OpenAIRE